Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. WHWK
stocks logo

WHWK

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Valuation Metrics

The current forward P/E ratio for Whitehawk Therapeutics Inc (WHWK.O) is -3.63, compared to its 5-year average forward P/E of -2.30. For a more detailed relative valuation and DCF analysis to assess Whitehawk Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.30
Current PE
-3.63
Overvalued PE
-1.31
Undervalued PE
-3.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.37
Current PS
0.00
Overvalued PS
3.31
Undervalued PS
1.43
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 230.74% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

WHWK News & Events

Events Timeline

(ET)
2025-12-01
08:20:00
Whitehawk Appoints Dr. Margaret Dugan as Chief Medical Officer
select
2025-11-06 (ET)
2025-11-06
08:07:59
Whitehawk Therapeutics Announces Q3 Earnings Per Share of 26 Cents, Compared to 46 Cents Last Year
select
2025-10-16 (ET)
2025-10-16
08:32:24
Tempus AI partners with Whitehawk Therapeutics to enhance cancer research
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-01PRnewswire
Whitehawk Appoints Dr. Dugan as CMO to Advance ADC Programs into Clinical Development
  • Leadership Enhancement: Whitehawk Therapeutics appoints Dr. Margaret Dugan, who has over 30 years of global oncology drug development experience, as Chief Medical Officer, aiming to leverage her expertise to enhance the company's clinical development capabilities in antibody-drug conjugates (ADCs) and accelerate their clinical progress.
  • Rich Clinical Development Experience: Dr. Dugan has overseen more than 12 Phase 1 clinical programs and successfully facilitated regulatory approvals for drugs like capmatinib and ceritinib, which will provide valuable regulatory strategy support for Whitehawk's ADC portfolio, enhancing its market competitiveness.
  • Rapid Advancement of Clinical Programs: While serving as CMO at Dracen Pharmaceuticals, Dr. Dugan successfully advanced the company's first clinical program through Phase 1 and secured Fast Track designation, an experience that will aid Whitehawk in achieving swift clinical translation for its ADC projects.
  • Innovative Treatment Prospects: Dr. Dugan emphasizes that Whitehawk's ADC portfolio features unique target selection and differentiated profiles, which are expected to offer significant therapeutic opportunities for patients with difficult-to-treat cancers, further solidifying the company's strategic position in oncology treatment.
[object Object]
Preview
1.0
11-26PRnewswire
Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

  • Company Announcement: Whitehawk Therapeutics, Inc. will have its President and CEO, Dave Lennon, participate in a fireside discussion at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025.

  • Event Details: The discussion will be accessible via a live webcast on the Whitehawk Therapeutics investor relations website, with a replay available for about 30 days post-event.

  • Company Focus: Whitehawk Therapeutics specializes in oncology therapeutics, utilizing advanced technologies to enhance antibody drug conjugate (ADC) cancer treatments.

  • Portfolio Information: The company has a three-asset ADC portfolio designed to address the limitations of earlier treatments, with these assets licensed from WuXi Biologics under an exclusive agreement.

[object Object]
Preview
1.0
11-11PRnewswire
Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London

  • Company Announcement: Whitehawk Therapeutics, Inc. will have its President and CEO, Dave Lennon, present at the Jefferies Global Healthcare Conference in London on November 18, 2025, at 11:30 AM GMT.

  • Webcast Availability: A live webcast of the presentation will be accessible on the Whitehawk Therapeutics investor relations website and will be available for replay for about 30 days post-event.

  • Company Overview: Whitehawk Therapeutics focuses on oncology therapeutics, utilizing advanced technologies to enhance antibody drug conjugate (ADC) cancer treatments, particularly for challenging cancers.

  • Partnership Details: The company’s ADC portfolio is developed under an exclusive agreement with WuXi Biologics, aimed at improving treatment outcomes for patients with difficult-to-treat cancers.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Whitehawk Therapeutics Inc (WHWK) stock price today?

The current price of WHWK is 2.56 USD — it has increased 14.29 % in the last trading day.

arrow icon

What is Whitehawk Therapeutics Inc (WHWK)'s business?

Whitehawk Therapeutics, Inc., formerly Aadi Bioscience, Inc., is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.

arrow icon

What is the price predicton of WHWK Stock?

Wall Street analysts forecast WHWK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for WHWK is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Whitehawk Therapeutics Inc (WHWK)'s revenue for the last quarter?

Whitehawk Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What is Whitehawk Therapeutics Inc (WHWK)'s earnings per share (EPS) for the last quarter?

Whitehawk Therapeutics Inc. EPS for the last quarter amounts to -0.26 USD, decreased -43.48 % YoY.

arrow icon

What changes have occurred in the market's expectations for Whitehawk Therapeutics Inc (WHWK)'s fundamentals?

The market is revising Downward the revenue expectations for Whitehawk Therapeutics, Inc. (WHWK) for FY2025, with the revenue forecasts being adjusted by -82.69% over the past three months. During the same period, the stock price has changed by 40.66%.
arrow icon

How many employees does Whitehawk Therapeutics Inc (WHWK). have?

Whitehawk Therapeutics Inc (WHWK) has 40 emplpoyees as of December 05 2025.

arrow icon

What is Whitehawk Therapeutics Inc (WHWK) market cap?

Today WHWK has the market capitalization of 120.65M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free